Abbott10-Q: Capex increaseJul 28, 2026

Abbott completes $20.6B acquisition of Exact Sciences, funded by $20B in new debt.

What happened

The acquisition establishes Abbott in the cancer diagnostics market but introduces significant integration costs, debt service, and operational complexity.

Source

SEC EDGARJul 28, 2026

Quarterly report (Form 10-Q)

Abbott 10-Q

Filing excerpt

On March 23, 2026, Abbott completed the acquisition of Exact Sciences for approximately $20.6 billion.

sec.gov/Archives/edgar/data/1800/000162828026050134/abt-20260630.htmRead the full source

Other signals in this filing (8)

RestructuringAbbott completes $20.6B acquisition of Exact Sciences, driving massive integration costs.RestructuringJul 28, 2026
Quality issueAbbott's $495M legal verdict related to infant formula quality was affirmed on appeal.Quality issueJul 28, 2026
Cost reductionSG&A expenses surge 30.3% ($934M) in Q2 due to acquisition integration and higher legal reserves.Cost reductionJul 28, 2026
Litigation materialCourt upholds $495M verdict against Abbott in infant formula lawsuit, with more cases pending.Litigation materialJul 28, 2026
Product launchAbbott launches new Libre® Duo biowearable in Europe after securing CE Mark in May 2026.Product launchJul 28, 2026
Margin pressureGross margin declined in Q2 2026 due to acquisition costs and inflation.Margin pressureJul 28, 2026
International growthAbbott's Medical Devices division sees double-digit growth, led by pacemakers and electrophysiology products.International growthJul 28, 2026
Inflation impactGross profit margin squeezed by the "unfavorable impact of higher costs."Inflation impactJul 28, 2026

Extracted by Autobound

From the Signal API record

Signal: 10-Q: Capex increase

What this signalsFilings often name leadership changes, deals and spending plans.

Fiscal year end: 06/30
Filed: Jul 28, 2026

More 10-Q signals at other companies

SEC 10-QMillerKnoll, Inc.Jeffrey M. Stutz appointed Interim Chief Executive Officer.SEC 10-QSep 28, 2026
SEC 10-QCID HoldCo, Inc.Disclosed material weaknesses in financial reporting due to insufficient accounting staff and controls.SEC 10-QSep 25, 2026
SEC 10-QScholastic CorporationCore school channels decline with fewer book fairs and lower club participation.SEC 10-QSep 25, 2026

The full record

From the Signal API record

Numbers

Dollar figure: $20.6B (Total acquisition cost for Exact Sciences)

Details

CIK: 1800
Accession number: 0001628280-26-050134
Timeframe: Current quarter
Filing year: 2026
Fiscal year: 0
Why it matters: Budget available
Signal category: Financial

Extraction

Confidence: High
Relevance: 95%
Sentiment: Neutral
Detected: Aug 4, 2026
signal_type: sec-10q
signal_subtype: capexIncrease

Use this data

Get every 10-Q signal for Abbott and the companies you sell to, in the tools you already use.

Ask Claude about it
Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Abbott this week?”
MCP setup guide
Send it to your own tools
The Signal API returns 10-Q signals for any list of companies as JSON, for your CRM, warehouse or app.
Signal API
Try it free
Sign up and spend your free credits on the companies you sell to.
Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full sec-10q record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

linkedin_urlValue in the API
industriesValue in the API
employee_count_lowValue in the API
employee_count_highValue in the API
revenueValue in the API
descriptionValue in the API

Signal

signal_nameValue in the API
associationValue in the API

Start Free1,000 free creditsUse it in Claude via MCP

Show the full JSONThe record on this page and the API request

GET /v1/signals/cd45bf2d-22ee-4f7a-9809-1554155a5e34 returns this record as JSON. POST /v1/companies/enrich returns every signal for abbott.com.

{
  "signal_id": "cd45bf2d-22ee-4f7a-9809-1554155a5e34",
  "signal_type": "sec-10q",
  "signal_subtype": "capexIncrease",
  "detected_at": "2026-08-04T07:04:02.81+00:00",
  "company": {
    "name": "Abbott",
    "domain": "abbott.com"
  },
  "data": {
    "detail": "The acquisition establishes Abbott in the cancer diagnostics market but introduces significant integration costs, debt service, and operational complexity. This creates opportunities for vendors specializing in post-merger integration, system consolidation, and financial management to support the transition.",
    "metrics": {
      "timeframe": "current_quarter",
      "dollar_context": "Total acquisition cost for Exact Sciences",
      "dollar_millions": 20600
    },
    "summary": "Abbott completes $20.6B acquisition of Exact Sciences, funded by $20B in new debt.",
    "excerpts": "On March 23, 2026, Abbott completed the acquisition of Exact Sciences for approximately $20.6 billion.",
    "relevance": 0.95,
    "sentiment": "neutral",
    "confidence": "high",
    "source_url": "https://www.sec.gov/Archives/edgar/data/1800/000162828026050134/abt-20260630.htm",
    "filing_date": "2026-07-28",
    "filing_year": 2026,
    "fiscal_year": 0,
    "fiscal_year_end": "06/30",
    "sales_relevance": "Budget available",
    "signal_category": "financial"
  }
}

curl https://signals.autobound.ai/v1/signals/cd45bf2d-22ee-4f7a-9809-1554155a5e34 \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"abbott.com","limit":20}'

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.